Larvol Veri

BIOMARKER:

CREBBP mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

CREBBP mutation CREBBP mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CREBBP mutation CREBBP mutation	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CREBBP mutation CREBBP mutation	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CREBBP mutation CREBBP mutation	Follicular Lymphoma Follicular Lymphoma	YF2 Sensitive: D – Preclinical YF2 Sensitive : D
CREBBP mutation CREBBP mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CDK6 inhibitor Sensitive: D – Preclinical CDK6 inhibitor Sensitive : D
CREBBP mutation CREBBP mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CDK4 inhibitor Sensitive: D – Preclinical CDK4 inhibitor Sensitive : D